All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The efficacy of ruxolitinib (RUX) is dependent on continuous administration in patients with myeloproliferative neoplasms.1 Discontinuation is associated with splenomegaly re-expansion and disease symptoms in myelofibrosis (MF) and increased hematocrit levels and disease symptoms in polycythemia vera (PV).1 Overall, poor adherence increases the risk of treatment failure.
Recently, Palandri et al.1 published results from the RAMP study (NCT06078319) in the Annals of Hematology, evaluating the incidence of low adherence to RUX and associated factors, including psychological stress, in patients with MF and PV.
Figure 1. Percentage of patients with MF or PV who completed all tests and declared A low adherence to RUX and B a high level of distress*
A
B
MF, myelofibrosis; PV, polycythemia vera.
*Adapted from Palandri, et al.1
Key learnings |
---|
|
Subscribe to get the best content related to MPN delivered to your inbox